|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Whilst numerous <i>in vitro</i> studies have investigated the molecular characteristics of CADM1 and CADM4 and <i>in vivo</i> studies have investigated CADM1 and CADM4 expression in a number of tumor types, the roles of CADM1 and CADM4 have yet to be elucidated.
|
29434950 |
2018 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Negative Necl-4 expression was significantly associated with a larger tumour size of >30 mm, perineural invasion, lymphatic involvement, lymph node metastasis (pN1), an advanced TNM (tumour, node, metastases) stage (stage IIB-IV), an advanced histological grade (G2/3), and shorter overall survival.
|
27980052 |
2017 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
These findings suggest that CADM4 is a novel tumor suppressor candidate in RCCC acting with its binding partner 4.1B.
|
21544807 |
2012 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
CADM-1, CADM-3, and CADM-4 have been shown to act as tumor suppressor genes in multiple cancers including prostate cancer.
|
21062931 |
2010 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Introduction of TSLL2 into PPC-1 strongly suppresses subcutaneous tumor formation in nude mice.
|
16261159 |
2006 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Loss of or low CADM4 expression was observed in 26 (15.3%) and 50 (29.4%) cases, respectively, and it was significantly associated with undifferentiated histology (p < 0.044), high-grade tumor (p < 0.001), high pT3 or pT4 stage (p < 0.038), pancreatic invasion (p < 0.018), and lymphatic invasion (p < 0.020).
|
28444978 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
RESULTS In colon adenocarcinomas, there was a significant association between Necl 4 and lymphovascular invasion, vascular invasion, and perineural invasion (p<0.05).
|
28561015 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
CADM4 expression was more preferentially lost in RCCC with vascular infiltration (p = 0.04), suggesting that loss of CADM4 is involved in tumor invasion.
|
21544807 |
2012 |
|
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
CADM-1, CADM-3, and CADM-4 have been shown to act as tumor suppressor genes in multiple cancers including prostate cancer.
|
21062931 |
2010 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
CADM-1, CADM-3, and CADM-4 have been shown to act as tumor suppressor genes in multiple cancers including prostate cancer.
|
21062931 |
2010 |
|
Malignant neoplasm of prostate
|
0.030 |
Biomarker
|
disease |
BEFREE |
TSLL2 protein is lost in nine of nine primary prostate cancers and in a prostate cancer cell, PPC-1.
|
16261159 |
2006 |
|
Prostate carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
TSLL2 protein is lost in nine of nine primary prostate cancers and in a prostate cancer cell, PPC-1.
|
16261159 |
2006 |
|
Malignant neoplasm of prostate
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Expression of TSLL1 and TSLL2 was lost or markedly reduced in many human glioma cell lines or some prostate cancer cell lines, suggesting that loss of expression of these genes might be involved in some human cancers.
|
11536053 |
2001 |
|
Prostate carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Expression of TSLL1 and TSLL2 was lost or markedly reduced in many human glioma cell lines or some prostate cancer cell lines, suggesting that loss of expression of these genes might be involved in some human cancers.
|
11536053 |
2001 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
While it has been reported that inactivation of CADM1 and CADM4 serves a pivotal role in the progression of breast cancer, a full analysis has not been completed for TNBC.
|
30655848 |
2019 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
While it has been reported that inactivation of CADM1 and CADM4 serves a pivotal role in the progression of breast cancer, a full analysis has not been completed for TNBC.
|
30655848 |
2019 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
The prognostic role of CADM1 and CADM4 in breast cancer was also evaluated and the expression of CADM1 and CADM4 were not associated with cancer-specific survival or overall survival rate in the cohort of patients in the present study.
|
29434950 |
2018 |
|
Breast Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
The prognostic role of CADM1 and CADM4 in breast cancer was also evaluated and the expression of CADM1 and CADM4 were not associated with cancer-specific survival or overall survival rate in the cohort of patients in the present study.
|
29434950 |
2018 |
|
Adenocarcinoma
|
0.020 |
Biomarker
|
group |
BEFREE |
CONCLUSIONS Necl 4 may have prognostic value in colon adenocarcinomas, but it is difficult to ascertain in gastric adenocarcinomas.
|
28561015 |
2017 |
|
Adenocarcinoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Loss of CADM4 expression is associated with poor prognosis in small intestinal adenocarcinomas.
|
28444978 |
2017 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
We demonstrate that activation of SHP (Small Heterodimer Partner), DKK4 (Dickkopf-4), and CADM4 (Cell Adhesion Molecule 4) by SRC-2 suppresses tumorigenesis in vitro and in vivo.
|
28273073 |
2017 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
The results suggest that Necl-4 is associated with carcinogenesis and aggressiveness of PDAC.
|
27980052 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
On multivariate analysis, SIA in the jejunum and ileum, (hazard ratio [HR], 2.465; 95% confidence interval [CI], 1.288-4.720; p = 0.006 and HR, 3.407; 95% CI, 1.515-7.662; p = 0.003, respectively), signet ring cell carcinoma (HR, 92.388; 95% CI, 14.813-576.230; p = 0.000), SIA with lymph node metastasis (HR, 3.223; 95% CI, 1.697-6.124; p = 0.000), retroperitoneal seeding (HR, 3.696; 95% CI, 1.303-10.479; p = 0.014), and CADM4 expression loss (HR, 2.348; 95% CI, 1.130-4.882; p = 0.022) were associated with poor OS.
|
28444978 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Negative Necl-4 expression was significantly associated with a larger tumour size of >30 mm, perineural invasion, lymphatic involvement, lymph node metastasis (pN1), an advanced TNM (tumour, node, metastases) stage (stage IIB-IV), an advanced histological grade (G2/3), and shorter overall survival.
|
27980052 |
2017 |
|
Triple Negative Breast Neoplasms
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In the present study, CADM1 and CADM4 expression was evaluated in patients with TNBC who had received PST.
|
30655848 |
2019 |